Radioimmunotherapy for treatment of b-cell lymphomas and other hematologic malignanciesPARK, Steven I; PRESS, Oliver W.Current opinion in hematology. 2007, Vol 14, Num 6, pp 632-638, issn 1065-6251, 7 p.Article

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseasePARK, Steven I; SHENOI, Jaideep; YUKANG LIN et al.Blood. 2010, Vol 116, Num 20, pp 4231-4239, issn 0006-4971, 9 p.Article

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelPAGEL, John M; KENOYER, Aimee L; OROZCO, Johnnie et al.Blood. 2011, Vol 118, Num 3, pp 703-711, issn 0006-4971, 9 p.Article

Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin LymphomaPARK, Steven I; SHENOI, Jaideep; KENOYER, Aimee L et al.Clinical cancer research (Print). 2011, Vol 17, Num 23, pp 7373-7382, issn 1078-0432, 10 p.Article

A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsPAGEL, John M; ORGUN, Nural; HAMLIN, Donald K et al.Blood. 2009, Vol 113, Num 20, pp 4903-4913, issn 0006-4971, 11 p.Article

Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primatesGREEN, Damian J; PAGEL, John M; GOPAL, Ajay K et al.Blood. 2009, Vol 114, Num 6, pp 1226-1235, issn 0006-4971, 10 p.Article